16 September 2026 editorial review · Trial
BRIGHT study of the implantable Indigo HALO multi-metabolite sensor: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT07745998; NOT_YET_RECRUITING; updated 2026-08-04; enrollment 12 (ESTIMATED); results not posted.
Endpoint comparison: Primary performance objective: Demonstration of Sensor accuracy (3 months); Primary performance objective: Demonstration of Sensor stability (3 months); Primary safety objective: Confirm safe implantation of the Sensor in human subcutaneous tissue (insertion procedural safety) (30 days); Primary safety objective: Confirm the safety of the device during the implantation period (3 months).
Sources for this record: NCT07745998: BRIGHT study of the Indigo HALO System (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.